In our study, the anti‐vascular activity of SHP099 is unlikely a consequence of an effect on the tumor cells, since the genetic depletion of SHP2 from the B16F10 tumor cells had no impact on the anti‐vascular and anti‐tumor activities of SHP099. This evidence concerns the gene PTPN11 and neoplasm.